Have you read this JDD case report on combination therapy for dissecting cellulitis of the scalp?
Have you read this article in JDD? This case report describes two men, ages 26 and 33, with refractory dissecting cellulitis of the scalp accompanied by hidradenitis suppurativa and acne conglobata who were treated with a combination regimen of bimekizumab, isotretinoin, and oral antibiotics. The authors report clinical improvement in scalp inflammation and stabilization of hair loss after the combination therapy was started.
Dissecting cellulitis of the scalp is a chronic inflammatory scalp disorder characterized by inflamed nodules, abscesses, and scarring hair loss, and it can coexist with other follicular occlusion disorders. This short report highlights a real world example of a multimodal approach using a biologic plus isotretinoin and antibiotics in patients with treatment refractory disease. The series is small and descriptive, so findings are not generalizable and do not establish efficacy. These cases nonetheless raise questions about whether combination therapy including bimekizumab may benefit select patients with refractory DCS and coexisting hidradenitis suppurativa or acne conglobata.
Read the full JDD report for case details, follow up data, and discussion, and consider whether these observations warrant further study or discussion within your clinical practice or research network.
J Drugs Dermatol. 2026;25(3). doi:10.36849/JDD.9259
Blog write-up assisted by AI
